Statement: There were more cases of deteriorating mental health in the primary trial than the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 6/110 (5.45%)   Sudden death unexplained 1/110 (0.91%)   General body pain 1/110 (0.91%)   Lymphangitis 1/110 (0.91%)   Femur fracture 1/110 (0.91%)   Parathyroid adenoma 1/110 (0.91%)   Depression worsened 1/110 (0.91%)   Calculus urinary bladder 1/110 (0.91%)   Pneumopathy 1/110 (0.91%)
Secondary_evidence: Adverse Events 1:   Total: 4/26 (15.38%)   Disseminated intravascular coagulation 1/26 (3.85%)   Cardiac failure congestive 1/26 (3.85%)   Breast cellulitis 1/26 (3.85%)   Cellulitis 1/26 (3.85%)   Acute myeloid leukaemia 1/26 (3.85%)   Seizure 0/26 (0.00%)   Pulmonary embolism 1/26 (3.85%) Adverse Events 2:   Total: 2/24 (8.33%)   Disseminated intravascular coagulation 0/24 (0.00%)   Cardiac failure congestive 0/24 (0.00%)   Breast cellulitis 0/24 (0.00%)   Cellulitis 1/24 (4.17%)   Acute myeloid leukaemia 0/24 (0.00%)   Seizure 1/24 (4.17%)   Pulmonary embolism 0/24 (0.00%)